Calidi Biotherapeutics shares are trading lower. The company announced that it expects to file an FDA Investigational New Drug application for its lead candidate, CLD-401, by the end of 2026.

Benzinga Newsdesk www.benzinga.com Negative 54.3%

Neg 54.3% Neu 0% Pos 0%

Comments

No comments yet. Be the first!